Serum levels of soluble molecules associated with evasion of immune surveillance: A study in biliary disease

Liver International

Volumn 24, Issue 4, 2004, Pages 330-334

  Enjoji, Munechika ^a   Yamaguchi, Koji ^a   Nakashima, Manabu ^b   Ohta, Satoshi ^a   Kotoh, Kazuhiro ^a   Fukushima, Marie ^a   Kuniyoshi, Masami ^a   Tanaka, Masao ^a   Nakamuta, Makoto ^a   Watanabe, Takeshi ^b   Nawata, Hajime ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cholangiocarcinoma; Cholangitis; Fas; Fas ligand; PBC; PSC; RCAS1

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CHOLANGITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

EID: 4444324266     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0931.x     Document Type: Article

References (26)

1. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806-13.
2. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995; 181: 1235-8.
3. French L E, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-43.
4. Griffith T S, Brunner T, Fletcher S M, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
5. Hahne M, Rimold D, Schroter M, et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-6.
6. O'connell J, O'sullivan G C, Collins J K, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
7. Stand S, Hoffmann W J, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nature Med 1996; 2: 1361-6.
8. Nihans G A, Brunner T, Frizelle S P, et al. Human lung carcinoma express Fas ligand. Cancer Res 1997; 57: 1007-12.
9. Saas P, Walker P R, Hahne M, et al. Fas ligand expressing by astrocytoma in vivo: maintaining immune privilege in the brain. J Clin Invest 1997; 99: 1173-8.
10. Midis G P, Shen Y, Owen-Schaub L B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996; 56: 3870-4.
11. Nagao M, Nakajima Y, Hisanaga M, et al. The alternation of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo. Hepatology 1999; 30: 413-21.
12. Tsutsumi S, Kuwano H, Shimura T, et al. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000; 89: 2560-4.
13. Mizutani Y, Hongo F, Sato N, et al. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001; 92: 287-93.
14. Hoffmann T K, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulation T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-62.
15. Bellone G, Smirne C, Carbone A, et al. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clin Cancer Res 2000; 6: 2448-55.
16. Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-6.
17. Schneider P, Holler N, Bodmer J L, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 205-13.
18. Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-50.
19. Sonoda K, Nakashima M, Kaku T, et al. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996; 77: 1501-9.
20. Iwasaki T, Nakashima M, Watanabe T, et al. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 2000; 89: 88-93.
21. Kubokawa M, Nakashima M, Yao T, et al. Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. Int J Oncol 2001; 19: 695-700.
22. Noguchi K, Enjoji M, Nakashima M, et al. Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett 2001; 168: 197-202.
23. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999; 5: 938-42.
24. Enjoji M, Nakashima M, Nishi H, et al. The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of the biliary tract. J Hepatol 2002; 36: 786-92.
25. Que F G, Phan VA, Phan V H, et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 1999; 30: 1398-404.
26. Shimonishi T, Isse K, Shibata F, et al. Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stage of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 2000; 32: 761-9.